Compare DexCom, Inc. (DXCM) vs Oscar Health Inc (OSCR) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Oscar Health (OSCR) trades at $30.73, down 1.09% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong revenue growth, with 2026 revenue projected at $13.3 billion, but remains unprofitable with a net margin of -0.3%. Recent news highlights its momentum, including a 102.8% year-to-date gain and positive coverage from The Motley Fool and Zacks.

The outlook is mixed: strong revenue growth and bullish technicals offer upside potential, but profitability challenges and a consensus price target below the current price signal caution. Key risks include execution in a competitive insurance market and sustained losses. Analyst sentiment is divided, with a hold-heavy consensus.